Fig. 1.

Effects on tumor growth in vivo. B16 cells were implanted on day 1. a Starting on day 3, groups of mice were treated with decitabine (DAC) and/or IL-2 for 2 weeks. A group was not treated (NT). Data represent mean tumor volume ± SEM, n = 10 mice per group. b Starting on day 3, groups of mice were treated with decitabine for 1 week and then IL-2 for 1 week (DAC → IL-2); IL-2 for 1 week and then decitabine for 1 week (IL-2 → DAC); or IL-2 for 2 weeks (IL-2). A group was not treated (NT). Data represent mean tumor volume ± SEM, n = 7 mice per group. c Starting on day 3, groups of mice were treated with DAC and/or ODN1826 (ODN) for 2 weeks. Data represent mean tumor volume ± SEM, n = 10 mice per group. d One week before tumor inoculation, groups of mice were immunized with rAAV-DCT. Starting on day 3, groups of mice were treated with DAC for 1 week and ODN for 1 week (AAV-DCT → DAC → ODN) or with ODN (AAV-DCT → ODN) for 1 week starting on day 10. Data represent mean tumor volume ± SEM, n = 7 mice per group